Future studies may identify additional growth factors provided by the in vivo tumor microenvironment that allow EBV-infected B cells with stricter forms of viral latency (where the EBV-encoded oncoproteins such as EBNA2, LMP1 and EBNA3C are not expressed) to proliferate in less immunogenic forms of EBV infection. This evidence concerns the gene PDLIM7 and Epstein-Barr virus infection.